FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387425334> ?p ?o ?g. }

• W4387425334 abstract "Pancreatic cancer is a malignant tumor with one of the worst prognosis. Its incidence has been on the rise in recent years. First-line and second-line treatments as well as adjuvant therapies have been employed in clinical trials for pancreatic cancer along with traditional chemotherapy and radiotherapy that has been enhanced. The prognosis of pancreatic ductal adenocarcinoma (PDAC) is still quite bad despite recent improvements in diagnostic and treatment methods. Since most patients are not candidates for treatment with a curative purpose, effective palliative care is crucial. For this systematic review, between December 25, 2022, and January 5, 2023, we searched PubMed, Medline, Cochrane, and Science Direct and discovered 225 relevant articles. The appropriateness of the literature abstracts for the pooled analysis was evaluated using different combinations of keywords such as pancreatic cancer, first- and second-line chemotherapy, palliative chemotherapy, gemcitabine and nab-paclitaxel (GnP), FOLFIRINOX (FFX), and fluorouracil. Eight research studies with a total of 15,236 people, including systematic reviews, meta-analyses, and randomized controlled trials (RCTs), were included. The only treatment of choice for patients without metastatic disease who have clinical staging that suggests resectable or borderline resectable pancreatic cancer (BRPC) should be resection. This research examined how first- and second-line chemotherapeutic regimens (using different drug combinations) affected patients with locally advanced pancreatic cancer (LAPC) or BRPC and how they responded in terms of overall survival (OS), tumor resectability, and progression-free interval. The review concludes by highlighting the results of these therapies. Notably, a growing body of research indicates that the two most popular first-line medication combinations GnP and FFX have similar results in RCTs and in real-world populations. Results of second-line therapy after first-line regime failure are still dismal, and there is still a great deal of doubt regarding the best course of action. More RCTs and real-world evidence studies that address current and innovative regimens, as well as the best order in which to administer them, are required, with a greater emphasis on targeted therapy with fewer side effects." @default.
• W4387425334 created "2023-10-08" @default.
• W4387425334 creator A5005789573 @default.
• W4387425334 creator A5006734562 @default.
• W4387425334 creator A5012886699 @default.
• W4387425334 creator A5021961300 @default.
• W4387425334 creator A5030210191 @default.
• W4387425334 creator A5030753500 @default.
• W4387425334 creator A5030863750 @default.
• W4387425334 creator A5087994426 @default.
• W4387425334 creator A5090759823 @default.
• W4387425334 date "2023-10-07" @default.
• W4387425334 modified "2023-10-18" @default.
• W4387425334 title "A Systematic Review of Chemotherapeutic Regimens Used in Pancreatic Cancer" @default.
• W4387425334 cites W1931508686 @default.
• W4387425334 cites W2128889451 @default.
• W4387425334 cites W2791015748 @default.
• W4387425334 cites W2811271347 @default.
• W4387425334 cites W2928824372 @default.
• W4387425334 cites W3028195043 @default.
• W4387425334 cites W3086844699 @default.
• W4387425334 cites W3118615836 @default.
• W4387425334 cites W3196455549 @default.
• W4387425334 cites W3216297924 @default.
• W4387425334 cites W4200002305 @default.
• W4387425334 cites W4296032642 @default.
• W4387425334 cites W4304757164 @default.
• W4387425334 doi "https://doi.org/10.7759/cureus.46630" @default.
• W4387425334 hasPublicationYear "2023" @default.
• W4387425334 type Work @default.
• W4387425334 citedByCount "0" @default.
• W4387425334 crossrefType "journal-article" @default.
• W4387425334 hasAuthorship W4387425334A5005789573 @default.
• W4387425334 hasAuthorship W4387425334A5006734562 @default.
• W4387425334 hasAuthorship W4387425334A5012886699 @default.
• W4387425334 hasAuthorship W4387425334A5021961300 @default.
• W4387425334 hasAuthorship W4387425334A5030210191 @default.
• W4387425334 hasAuthorship W4387425334A5030753500 @default.
• W4387425334 hasAuthorship W4387425334A5030863750 @default.
• W4387425334 hasAuthorship W4387425334A5087994426 @default.
• W4387425334 hasAuthorship W4387425334A5090759823 @default.
• W4387425334 hasBestOaLocation W43874253341 @default.
• W4387425334 hasConcept C121608353 @default.
• W4387425334 hasConcept C126322002 @default.
• W4387425334 hasConcept C143998085 @default.
• W4387425334 hasConcept C17744445 @default.
• W4387425334 hasConcept C189708586 @default.
• W4387425334 hasConcept C199539241 @default.
• W4387425334 hasConcept C2776478404 @default.
• W4387425334 hasConcept C2776694085 @default.
• W4387425334 hasConcept C2777148230 @default.
• W4387425334 hasConcept C2779473830 @default.
• W4387425334 hasConcept C2780210213 @default.
• W4387425334 hasConcept C2780258809 @default.
• W4387425334 hasConcept C2780259306 @default.
• W4387425334 hasConcept C526805850 @default.
• W4387425334 hasConcept C535046627 @default.
• W4387425334 hasConcept C71924100 @default.
• W4387425334 hasConcept C95190672 @default.
• W4387425334 hasConceptScore W4387425334C121608353 @default.
• W4387425334 hasConceptScore W4387425334C126322002 @default.
• W4387425334 hasConceptScore W4387425334C143998085 @default.
• W4387425334 hasConceptScore W4387425334C17744445 @default.
• W4387425334 hasConceptScore W4387425334C189708586 @default.
• W4387425334 hasConceptScore W4387425334C199539241 @default.
• W4387425334 hasConceptScore W4387425334C2776478404 @default.
• W4387425334 hasConceptScore W4387425334C2776694085 @default.
• W4387425334 hasConceptScore W4387425334C2777148230 @default.
• W4387425334 hasConceptScore W4387425334C2779473830 @default.
• W4387425334 hasConceptScore W4387425334C2780210213 @default.
• W4387425334 hasConceptScore W4387425334C2780258809 @default.
• W4387425334 hasConceptScore W4387425334C2780259306 @default.
• W4387425334 hasConceptScore W4387425334C526805850 @default.
• W4387425334 hasConceptScore W4387425334C535046627 @default.
• W4387425334 hasConceptScore W4387425334C71924100 @default.
• W4387425334 hasConceptScore W4387425334C95190672 @default.
• W4387425334 hasLocation W43874253341 @default.
• W4387425334 hasOpenAccess W4387425334 @default.
• W4387425334 hasPrimaryLocation W43874253341 @default.
• W4387425334 hasRelatedWork W1801064348 @default.
• W4387425334 hasRelatedWork W2094153719 @default.
• W4387425334 hasRelatedWork W2126322332 @default.
• W4387425334 hasRelatedWork W2596055884 @default.
• W4387425334 hasRelatedWork W2885862304 @default.
• W4387425334 hasRelatedWork W3008650849 @default.
• W4387425334 hasRelatedWork W3031244932 @default.
• W4387425334 hasRelatedWork W3031675857 @default.
• W4387425334 hasRelatedWork W4205828341 @default.
• W4387425334 hasRelatedWork W4312740814 @default.
• W4387425334 isParatext "false" @default.
• W4387425334 isRetracted "false" @default.
• W4387425334 workType "article" @default.